Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for symbols : Bmy save search
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $4.6 -0.86% 130K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
Published: 2024-03-18 (Crawled : 15:30) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.46%
H: 0.23%
C: -1.88%
acquisition therapeutics
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-03-15 (Crawled : 23:00) - biospace.com/
TSVT | $4.6 -0.86% 130K
|
|
| O: 2.27%
H: 8.4%
C: -0.99%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.32%
H: 1.67%
C: 0.04%
fda therapy
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
Published: 2024-03-11 (Crawled : 23:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.2%
H: 1.22%
C: 0.85%
first report results
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.23%
H: 0.44%
C: 0.14%
drug review food tumors treatment application advanced
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
Published: 2024-02-07 (Crawled : 13:30) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
lung opdivo cancer cell
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Published: 2024-02-02 (Crawled : 14:30) - biospace.com/
RYZB | $62.49 0.03% 280K
|
|
| O: 0.03%
H: 0.11%
C: 0.0%
XYF | News | $3.745 -0.93% 1.8K
|
Finance
|
| O: 1.04%
H: 1.79%
C: -1.23%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
financial results
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.36%
H: 0.26%
C: -1.32%
breyanzi japan cell
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
Published: 2024-01-02 (Crawled : 14:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.27%
H: 3.89%
C: 2.55%
lung tumors cancer cell treatment application advanced
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Published: 2023-12-22 (Crawled : 20:00) - biospace.com/
PTCHF | $2.78 19.97% 560
|
n/a
|
| O: 29.67%
H: 0.0%
C: -5.76%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.78%
H: 5.15%
C: 2.81%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 47.74%
H: 0.0%
C: 0.0%
therapeutics acquired
Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published: 2023-12-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 3.66%
H: 0.0%
C: -0.12%
AZNCF | $138.24 800
|
Health Technology
|
| O: 3.33%
H: 0.0%
C: -2.93%
NVO | $123.43 0.55% 1.4M
|
Health Technology
|
| O: -0.31%
H: 0.39%
C: -0.44%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
LLY | $731.1 -1.99% 1M
|
Health Technology
|
| O: 0.18%
H: 0.5%
C: -0.46%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.78%
H: 5.15%
C: 2.81%
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
REGN | $894.35 0.04% 140K
|
Health Technology
|
| O: 0.52%
H: 0.58%
C: 0.05%
GILD | News | $66.495 0.51% 1.9M
|
Health Technology
|
| O: 0.34%
H: 1.02%
C: 0.59%
BIIB | $191.45 0.49% 310K
|
Health Technology
|
| O: 0.57%
H: 1.36%
C: 1.04%
AZN | $68.545 0.27% 1.2M
|
Health Technology
|
| O: 1.06%
H: 0.18%
C: -1.06%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.24%
H: 2.03%
C: 1.49%
patent report global market
Antipsychotic Drugs Market Forecasts 2023-2028 - Market Set for Growth, Forecasted at CAGR of 5.94% from 2023 to 2028
Published: 2023-12-15 (Crawled : 23:00) - prnewswire.com
BMY | $48.56 0.54% 1.8M
|
Health Technology
| Email alert
Add to watchlist
LLY | $731.1 -1.99% 1M
|
Health Technology
| Email alert
Add to watchlist
set market
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
Published: 2023-12-15 (Crawled : 22:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.6%
H: 0.57%
C: -0.53%
report results
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
treatment lymphomas potential
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
TSVT | $4.6 -0.86% 130K
|
|
| O: -4.02%
H: 9.35%
C: 4.84%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
therapy
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab)
Published: 2023-12-05 (Crawled : 16:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -0.36%
H: 1.2%
C: 0.86%
drug opdivo review food application
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
Published: 2023-11-28 (Crawled : 20:00) - biospace.com/
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: 0.06%
H: 0.55%
C: -0.27%
RNA | $22.91 -0.56% 180K
|
Health Technology
|
| O: 25.32%
H: 3.63%
C: -8.29%
expansion collaboration technology cardiovascular platform
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Published: 2023-11-20 (Crawled : 13:00) - biospace.com/
TSVT | $4.6 -0.86% 130K
|
|
| O: -11.74%
H: 1.06%
C: -7.45%
BMY | $48.56 0.54% 1.8M
|
Health Technology
|
| O: -4.05%
H: 2.85%
C: 0.25%
fda review update therapy
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.